Showing 861 - 880 results of 68,600 for search '(( 5 ((we decrease) OR (mean decrease)) ) OR ( 100 ((teer decrease) OR (a decrease)) ))', query time: 1.30s Refine Results
  1. 861
  2. 862
  3. 863

    S1 Data - by Toru Hosokawa (364158)

    Published 2023
    Subjects:
  4. 864

    Multicenter Phase 2 Trial of Sirolimus for Tuberous Sclerosis: Kidney Angiomyolipomas and Other Tumors Regress and VEGF- D Levels Decrease by Sandra L. Dabora (206838)

    Published 2011
    “…Kidney angiomyolipomas regrew when sirolimus was discontinued but responses tended to persist if treatment was continued after week 52. We observed regression of brain tumors (SEGAs) in 7/11 cases (26% mean decrease in diameter), regression of liver angiomyolipomas in 4/5 cases (32.1% mean decrease in longest diameter), subjective improvement in facial angiofibromas in 57%, and stable lung function in women with TSC/LAM (n = 15). …”
  5. 865
  6. 866
  7. 867
  8. 868
  9. 869
  10. 870

    APB5, but not APA5, decreases apoptosis in alveolar epithelial cells in lungs of BLM-treated mice. by Masami Kishi (6167105)

    Published 2018
    “…The administration of APA5 did not change the number of TUNEL-positive cells from that in BLM-treated mice, whereas that of APB5 significantly decreased them. …”
  11. 871
  12. 872
  13. 873

    Table_1_A phased intervention bundle to decrease the mortality of patients with extracorporeal membrane oxygenation in intensive care unit.pdf by Yajun Jing (11711139)

    Published 2022
    “…</p>Results<p>The cohort included 297 patients in 6 ICUs, mostly VA ECMO (68.7%) with a median (25th–75th percentile) duration in ECMO of 9.0 (4.0–15.0) days. The mean (SD) APECHII score was 24.1 (7.5). Overall, the mortality of ECMO decreased from 57.1% at baseline to 21.8% at 13–18 months after implementation of the study intervention (P < 0.001). …”
  14. 874
  15. 875
  16. 876
  17. 877
  18. 878
  19. 879
  20. 880